Health
Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer – OncLive
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be…
Updated survival data from the phase 3 Short-HER trial (NCT00629278) presented during the ESMO Breast Cancer Virtual Congress 2021confirm the promising long-term results obtained with 9 weeks of adjuvant trastuzumab (Herceptin) in patients with HER2-positive early breast cancer who have low and intermediate risk factors, a population that is representative of most patients seen in clinical practice.1After a median follow-up of 8.7 years, patients who received 1 year of trastuzumab had a 5-year disease-free…
-
Business21 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General21 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News7 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General21 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts